Restructuring for Global Portfolio Optimization

Amgen (AMGN) is undergoing organizational changes, laying off 40 employees, which represents approximately 0.1% of its global workforce. This move goes beyond simple cost-cutting and can be interpreted as a strategic effort to streamline its portfolio, focusing on core assets in response to recent pipeline adjustments and regulatory pressures. The company has pledged to provide transition support to affected employees, demonstrating its commitment to operational efficiency. This decision follows a merger and acquisition (M&A) and aims to consolidate overlapping departments and allocate resources to high-value projects.

Regulatory Pressure on Tavneos and Defense at FDA Hearing

Amgen's rare disease treatment, Tavneos (avacopan), is facing significant regulatory scrutiny in the United States and Europe due to concerns regarding safety and clinical data integrity. This C5a Receptor Antagonist, approved by the FDA in October 2021 for the treatment of ANCA-Associated Vasculitis, is now at risk of being withdrawn from the market due to concerns about Liver Toxicity. Amgen has rejected the FDA's voluntary withdrawal recommendation and requested a hearing, submitting validation data re-evaluating the Phase 3 clinical trial data (ADVOCATE Trial). With annual sales of $459 million (USD) in 2025, the ultimate fate of Tavneos will directly impact Amgen's short- to medium-term rare disease revenue.

Pipeline Restructuring and Partnership Termination

To focus on key areas, Amgen is aggressively streamlining its pipeline, discontinuing projects that are underperforming or considered high-risk. The company terminated its collaboration with Kyowa Kirin on rocatinlimab (AMG 451), a treatment for atopic dermatitis, for which it had made an upfront payment of $400 million (USD) and potential milestone payments of up to $850 million (USD) in 2021. Subsequently, rocatinlimab's global clinical trials were halted due to significant safety concerns, including the potential for Kaposi's Sarcoma and other malignancies. Additionally, Amgen prematurely terminated the Phase 2 clinical trial for adezkibart (AMG 329), a treatment for Sjögren's Disease, and the Phase 1 clinical trial for AMG 378, an oral small molecule treatment for Ulcerative Colitis, to minimize losses from failed assets.

Launching Next-Generation Pipeline to Secure New Momentum

Despite these challenges, Amgen is focusing on subsequent pipeline clinical trials to secure new growth drivers. Dazdilimab, acquired through the $27.8 billion (USD) acquisition of Horizon Therapeutics, has demonstrated promising results in the Phase 2 clinical trial for Discoid Lupus Erythematosus, meeting the primary endpoint in February. Furthermore, maritide (maridebart cafraglutide), a next-generation obesity treatment, is generating significant market interest and is currently undergoing six Phase 3 clinical trials (Maritime Trials). Top-line data from these trials is expected to be released next year, and Amgen is poised to compete directly with Eli Lilly and Novo Nordisk in the obesity and metabolic disease market.

Why This Matters

The FDA hearing to defend Tavneos' $459 million in sales is a critical turning point for short-term revenue protection. In the medium to long term, the success of dazdilimab's Phase 2 lupus trial, acquired through the $27.8 billion Horizon acquisition, and the Phase 3 results of dazodalibep, a treatment for Sjögren's Disease, will diversify Amgen's immunology portfolio. Furthermore, the release of top-line data from maritide's Phase 3 trials, expected next year, will determine the competitive landscape in the approximately $100 billion global obesity treatment market, with Amgen, Eli Lilly, and Novo Nordisk vying for market share. This restructuring is part of a strategic realignment to eliminate accumulated early pipeline risks, such as the termination of the rocatinlimab partnership and the discontinuation of adezkibart's Phase 2 trial, and reallocate resources to high-growth areas.